Quantcast

Latest Biogen Idec Stories

2014-06-10 12:30:16

CHICAGO, June 10, 2014 /PRNewswire-USNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced a key partnership with Biogen Idec in support of the PFF Patient Registry. The PFF announced its plan to establish a PFF Patient Registry, along with a PFF Care Center Network (CCN), at its biennial PFF Summit held in December 2013. "Our partnership with Biogen Idec will further enhance the PFF Patient Registry, allowing us to investigate fundamentally important questions in...

2014-06-09 08:28:10

Isis Earns $14 Million Milestone Payment from Biogen Idec CARLSBAD, Calif., June 9, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPK(Rx). Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement. ISIS-DMPK(Rx) is designed to reduce the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of...

2014-05-28 08:33:06

Array to advance kinase inhibitors for inflammatory disease BOULDER, Colo., May 28, 2014 /PRNewswire/ -- Array BioPharma (Nasdaq: ARRY) announced today a collaboration agreement with Biogen Idec (NASDAQ: BIIB) for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO The collaboration target and lead inhibitors were discovered through Array's proprietary...

2014-05-27 08:27:32

MISSISSAUGA, ON, May 27, 2014 /CNW/ - Biogen Idec Canada announces today that TECFIDERA(TM) (dimethyl fumarate) is now available for reimbursement in Ontario through the Ontario Public Drugs Program's (OPDP) Exceptional Access Program (EAP), as indicated in the upcoming May 29, 2014, Edition No. 42, Ontario Drug Benefit Formulary/Comparative Index. TECFIDERA(TM) is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERA(TM) is indicated as...

2014-05-26 12:23:04

PISA, Italy and HONG KONG, May 26, 2014 /PRNewswire/ -- Abiogen Pharma S.p.A. of Pisa Italy and Lee's Pharm jointly announced the agreement for License, Distribution and Supply for marketing of Attila(R) (Neridronic Acid) throughout China, Hong Kong, Macau and Taiwan. Under the term of the agreement, Abiogen Pharma S.p.A. granted Lee's Pharm an exclusive license and right for registering, importing, marketing, distributing and selling Attila(R) in the territory, for the two...

2014-05-22 08:26:27

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, May 22, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited...

2014-05-20 23:14:15

After Ranking 2nd on the Boston Business Journals List of Meeting and Event Planners, Boston's Foremost Event Planning and Destination Management Company Boston Eventworks Inc. has hired Event Specialist Adam Small. With a strong background in audio and visual production and social media stemming from his time with FOX Broadcasting Company, Small will produce and manage corporate events and accounts. Boston, MA (PRWEB) May 20, 2014 Boston Eventworks, Inc. ranked 2nd among Boston...

2014-05-12 12:28:55

Editor Note: For more information about this release, please scroll to bottom. LONDON, May 12, 2014 /PRNewswire/ -- On Friday, May 09, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, and...

2014-05-07 12:29:28

Amplimmune, Inc. and Medimmune are honored as the best deals in Mergers and Acquisitions and Isis Pharmaceuticals and Biogen Idec for Biopharmaceutical Licensing PHILADELPHIA, May 7, 2014 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, honored Amplimmune, Inc. and Medimmune for their work in pharmaceutical Mergers and Acquisitions (M&A), and Isis...

2014-05-06 16:32:43

Partnership with Biogen Idec and Recent Follow-on Financing Enhance Cash Position RICHMOND, Calif., May 6, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2014 financial results and accomplishments. http://photos.prnewswire.com/prnvar/20130102/SF35903LOGO For the first quarter ended March 31, 2014, Sangamo reported a consolidated net loss of $7.6 million, or $0.12 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related